The Fractional Excretion of Sodium (FENa) determines if renal failure is due to pre-renal, intrinsic, or post-renal pathology.

2018年5月16日 · Pearl 1: Diagnostic criteria for Contrast-Induced Nephropathy (CIN) Most research studies define CIN as a relative increase in serum creatinine of anywhere from 25-50% or, an absolute rise in serum creatinine of 0.5 to 1mg/dL within 48-72 hours after exposure to contrast with exclusion of other causes of acute kidney injury.

2018年5月16日 · Other clues are signs of acute tubular necrosis and a fractional excretion of sodium (FeNA) less than 1. Most data suggest that CIN is a disease entity almost entirely reserved for patients undergoing intra-arterial contrast loads, and not intra-venous contrast loads.

Contrast-induced nephropathy (CIN) is a serious complication of angiographic procedures resulting from the administration of contrast media (CM). It is the third most common cause of hospital acquired acute renal injury and represents about 12% of ...

2024年10月30日 · The fractional excretion of sodium (FENa) measures the percent of filtered sodium that is excreted in the urine. This calculation is used to help differentiate prerenal …

2024年6月5日 · Contrast-induced nephropathy (CIN) is defined as the impairment of renal function and is measured as either a 25% increase in serum creatinine (SCr) from baseline or 0.5...

Contrast-induced nephropathy (CIN) is a purported form of kidney damage in which there has been recent exposure to medical imaging contrast material without another clear cause for the acute kidney injury.

One important potential side-effect of iodinated contrast administration is contrast-induced nephropathy (CIN, see Appendix A for a list of acronyms), defined as an increase in serum creatinine of more than 25 percent or 0.5 mg/dL within 3 days of intravascular administration of contrast media in the absence of an alternative etiology.1 This ...

2014年11月4日 · Several risk markers have been implicated in the pathogenesis of CIN: Pre-existing renal impairment is the strongest predictor of CIN as consistently shown in virtually all related studies. Patients with substantial decrease in renal function before the procedure have a tenfold risk of CIN when compared to patients with normal renal function (7).

2024年11月5日 · CinFina Pharma, a CinRx portfolio company, is advancing a pipeline of high-impact monotherapies and combination treatments for people with obesity. GLP-1’s have made significant progress to help patients with obesity achieve weight loss goals and improve associated comorbidities.